From: Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration
Compound
Route
Cmax (ng/mL)
Tmax (h)
AUCt ng/mL*h)
Bioavailability
Brain Concentration (24 h) (ng/mL)
VCE-003.2
IV
83160
0.08
475094.96
93.7 ± 37.7
ORAL
20266.67
8
327154.14
13.77%
86.8 ± 34.0